Israeli Health Tech Is Heating Up With A Wave Of Interest From Abroad.
Israel’s many health tech startups are attracting unprecedented interest from abroad, with multinational medical giants looking to benefit from the country’s ongoing high-tech boom. Considering that life sciences alone represent nearly 50 percent of scientific research in Israel, the country has become a hub for medical and health innovation and, consequently, a target for investors.
According to a 2015 report by Israel Advanced Technology Industries, Israeli life sciences companies raised more than $1.4 billion on the NASDAQ in 2014. Out of all the 73 biotech life sciences IPOs in 2014, 7 were Israeli. Furthermore, Venture Capital (IVC) Research Center, revealed — in the same report — that $801 million was invested in 167 life sciences companies, a figure 55 percent higher than the previous year.
Israeli startup exits have raised $3.8B so far in 2015, more than 2014.
The first three quarters of 2015 have been a huge achievement for Israel, which has seen $3.8 billion in mergers and acquisitions according to a survey by Israeli financial newspaper Globes.
The survey differentiates between biotech companies and other startups, though combined, that $3.8 billion figure so far this year is $500 million more than in all of 2014. The biggest acquisition in biomed was Valtech Cardio for nearly $1 billion to U.S.-based Heartware
. For non medical startups, Annapurna Labs scored $360 million selling itself to Amazon.
Shareholder Novartis To Invest Additional $15 Million In Israeli Co Gamida Cell.
Multinational pharmaceutical giant Novartis International AG has announced that it is investing up to an additional $15 million in Israeli Gamida Cell . Gamida Cell develops cellular and immune therapies for the treatment of cancer and orphan genetic diseases.
A Three-foot Long Baby… and Other Scary Data Errors in Clinical Trials. Some of the
statistics and data entered in clinical trials are more appropriate for the cover of National Enquirer than a scientific study. Can you imagine a three-foot long newborn baby? And the idea of 75 drinks a week also may raise some eyebrows. But these are just a couple of the real life examples of the freakish data errors that can slip between the cracks in clinical trials.
Tech: A Catalyst to Bring Change to Clinical Research.
mHealth Tomasz Sablinski gave a compelling talk at NYAS mHealth conference on how to overcome the perceived challenges of introducing tech in clinical research as well as how he sees it being implemented. There are too many opportunities with existing and future mobile sensors, devices and technology to ignore the potential.
Now live! Our new translations division of high quality certified medical and pharmaceutical translations. You are welcome to visit our new webpage: www.qt-translations.com